Clearside Biomedical, Inc. to Participate in Stifel 2017 Healthcare Conference
November 13 2017 - 4:30PM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical
biopharmaceutical company developing first-in-class drug therapies
to treat back-of-the-eye diseases, announced today that its Chief
Executive Officer and President, Daniel H. White, will present at
the Stifel 2017 Healthcare Conference on Wednesday, November 15,
2017 at 1:15 p.m. ET at the Lotte New York Palace Hotel.
A live webcast of the presentation can be accessed on the
company’s website at www.clearsidebio.com under the “Events &
Presentations” tab in the “Investor Relations” section. Following
the conference, the presentation webcast will be archived on the
website for 30 days.
About Clearside
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is
a late-stage clinical ophthalmic biopharmaceutical company that
envisions a world without blindness. Clearside relentlessly
pursues transformative, elegant, precise solutions to restore and
preserve vision. Clearside is developing advanced clinical and
nonclinical product candidates using a proprietary treatment
approach offering unprecedented access to the back of the eye
through the suprachoroidal space (SCS™). This offers potentially
meaningful treatment benefit to patients suffering from sight
threatening diseases like uveitis, retinal vein occlusion, diabetic
macular edema and wet age-related macular degeneration. To learn
more about how Clearside is changing ophthalmology, please visit us
at www.clearsidebio.com.
Contacts:
Stephen KilmerInvestor Relations(678)
270-3631stephen.kilmer@clearsidebio.com
Charles DeignanChief Financial Officer(678)
270-4005charlie.deignan@clearsidebio.com
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Sep 2023 to Sep 2024